Xenon Pharmaceuticals. has filed a patent for pharmaceutical compositions containing Compound A for treating diseases associated with Naj4.6 activity. The patent includes an immediate release tablet formulation with specific excipients. The invention aims to provide effective treatment options for conditions like epilepsy. GlobalData’s report on Xenon Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Xenon Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Xenon Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Xenon Pharmaceuticals's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Immediate release tablet for treatment of epilepsy

Source: United States Patent and Trademark Office (USPTO). Credit: Xenon Pharmaceuticals Inc

The patent application US20230404913A1 discloses an immediate release tablet containing a specific compound, (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or its pharmaceutically acceptable salt. The tablet formulation includes various pharmaceutically acceptable ingredients such as diluents, disintegrants, glidants, wetting agents, and lubricants. Additionally, the tablet may have a film coating, with an aqueous film coating containing Opadry II being a specific example mentioned in the claims.

Furthermore, the patent application describes granular formulations that can be reconstituted with a carrier to form a stable suspension oral dosage form. These granular formulations contain Compound A or its salt along with excipients like fillers, binders, and lubricants. The application also covers methods of administering Compound A to patients in need, including reconstituting the granular formulation to create a stable suspension oral dosage form and orally administering it. Additionally, there is a mention of a multiparticulate sprinkle dosage form that can be sprinkled on soft food for oral administration, with examples of soft foods provided in the claims. The patent application also includes a method of treating diseases or conditions associated with NaV1.6 activity, such as epilepsy, by administering the immediate release tablet containing Compound A.

To know more about GlobalData’s detailed insights on Xenon Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies